CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Sponsor: University of Pennsylvania
Terminated
Administrative reasons
A PHASE1 clinical study on Acute Myeloid Leukemia, Pediatric and Acute Myeloid Leukemia, Refractory, this trial is terminated or withdrawn. The trial is conducted by University of Pennsylvania and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Mar 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
▶ Show 6 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .